Radius Health, Inc. announced topline results from a Phase 2 study of BA058, or abaloparatide, the company's novel synthetic peptide analog of PTHrP (human parathyroid hormone-related protein, a naturally occurring bone-building hormone) in development for the treatment of osteoporosis. The Phase 2 trial compared abaloparatide delivered via self-administered subcutaneous injection (Abaloparatide SC) with administration via a short wear-time transdermal patch (Abaloparatide TD) based on 3M's patented Microstructured Transdermal System technology. The Abaloparatide TD program is part of Radius' commitment to better meet patient needs through the development of this novel, patient-friendly, injection-free, short wear-time skin patch.